Pfizer Analysts Cut Their Forecasts Following Q3 Results
Portfolio Pulse from Lisa Levin
Pfizer Inc reported a loss for Q3 with a 42% slump in sales to $13.23 billion, down from $22.64 billion a year ago. Despite this, the company beat the consensus of $12.72 billion. Following the earnings announcement, Morgan Stanley and Barclays lowered their price targets on Pfizer.
November 01, 2023 | 6:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer reported a Q3 loss and a significant slump in sales. Analysts from Morgan Stanley and Barclays have lowered their price targets on the company.
Pfizer's Q3 loss and sales slump are negative indicators for the company's financial health. This has led analysts to lower their price targets, which could negatively impact investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100